TAK-653

• 30 mL liquid solution
• Concentration: 5 mg per mL
• Total content: 150 mg

Research indicates TAK-653 modulates excitatory neurotransmission through AMPA-receptor potentiation: This mechanism places TAK-653 in the same conceptual class as ampakines, though with a more refined safety and selectivity profile in preclinical models.

• Acts as a positive allosteric modulator of AMPA receptors
• Enhances glutamate signaling only when receptors are activated
• Improves synaptic-transmission efficiency
• Promotes long-term potentiation (LTP)
• Increases downstream neuroplasticity signaling, including BDNF-related pathways
• Avoids the direct glutamate overstimulation associated with agonists

TAK-653 is commonly studied in

• Cognitive-enhancement and learning models
• Synaptic-plasticity and LTP research
• Depression- and anhedonia-related pathways
• Executive-function and working-memory studies
• Neuroplasticity and BDNF-signaling research
• Cognitive-impairment and age-related-decline models

Reported or historically noted findings include: Because TAK-653 modulates excitatory signaling, excessive dosing may increase cortical excitability in sensitive models.

• Headache
• Mild insomnia when administered late in the wake cycle
• Restlessness at higher doses
• Transient nausea in some models
• No significant neurotoxicity reported in controlled preclinical studies

Researchers generally avoid combining TAK-653 with other strong glutamatergic modulators or high-dose stimulants to prevent excessive excitatory signaling.